Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
Total Valuation
Dyne Therapeutics has a market cap or net worth of $1.13B. The enterprise value is $1.79B.
Market Cap$1.13B
Enterprise Value$1.79B
Share Statistics
Dyne Therapeutics has 113,633,780 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding113,633,780
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Dyne Therapeutics’s return on equity (ROE) is -0.50 and return on invested capital (ROIC) is -52.60%.
Return on Equity (ROE)-0.50
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-52.60%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee0.00
Profits Per Employee-1.66M
Employee Count191
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dyne Therapeutics is -6.99. Dyne Therapeutics’s PEG ratio is 0.48.
PE Ratio-6.99
PS Ratio―
PB Ratio3.52
Price to Fair Value3.52
Price to FCF-7.53
Price to Operating Cash Flow-7.59
PEG Ratio0.48
Income Statement
In the last 12 months, Dyne Therapeutics had revenue of 0.00 and earned -317.42M in profits. Earnings per share was -3.37.
Revenue0.00
Gross Profit0.00
Operating Income-343.89M
Pretax Income-317.42M
Net Income-317.42M
EBITDA-343.89M
Earnings Per Share (EPS)-3.37
Cash Flow
In the last 12 months, operating cash flow was -292.37M and capital expenditures -2.38M, giving a free cash flow of -294.75M billion.
Operating Cash Flow-292.37M
Free Cash Flow-294.75M
Free Cash Flow per Share-2.59
Dividends & Yields
Dyne Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.87
52-Week Price Change-53.12%
50-Day Moving Average11.23
200-Day Moving Average26.36
Relative Strength Index (RSI)59.16
Average Volume (3m)2.47M
Important Dates
Dyne Therapeutics upcoming earnings date is May 1, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Dyne Therapeutics as a current ratio of 15.60, with Debt / Equity ratio of 3.81%
Current Ratio15.60
Quick Ratio15.60
Debt to Market Cap0.01
Net Debt to EBITDA1.20
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dyne Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dyne Therapeutics EV to EBITDA ratio is -5.25, with an EV/FCF ratio of -6.13.
EV to Sales0.00
EV to EBITDA-5.25
EV to Free Cash Flow-6.13
EV to Operating Cash Flow-6.18
Balance Sheet
Dyne Therapeutics has $642.27M in cash and marketable securities with $126.00M in debt, giving a net cash position of -$618.28M billion.
Cash & Marketable Securities$642.27M
Total Debt$126.00M
Net Cash-$618.28M
Net Cash Per Share-$5.44
Tangible Book Value Per Share$6.69
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Dyne Therapeutics is $48.64, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$48.64
Price Target Upside337.80% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast14.93%